Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448625 | 0.79 | MKNK1 (0.40) | — | |
| SCHEMBL3374359 | 0.78 | XDH (0.33) | PTGS2EGFR | |
| SCHEMBL3450897 | 0.77 | KDM4E (0.38) | — | |
| SCHEMBL3725252 | 0.75 | GAA (0.39) | — | |
| SCHEMBL2884934 | 0.75 | ALDH1A1 (0.35) | — | |
| SCHEMBL12614924 | 0.75 | XDH (0.46) | PTGS2MAP4K4 | |
| SCHEMBL1098645 | 0.73 | SCN9A (0.50) | P4HTMPTGS2SCN9ACHEK1SCN5A | |
| SCHEMBL1450741 | 0.72 | — | — | |
| SCHEMBL2073622 | 0.71 | P4HTM (0.43) | P4HTMSCN9ASCN5APTPN1 | |
| SCHEMBL1820805 | 0.71 | HDAC1 (0.66) | P4HTMPTGS2PTGS1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | claimed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | claimed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | P4HTM 2264/4885PTGS2 224/4885SCN9A 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.